Tourmaline Bio (TRML) Stock Forecast, Price Target & Predictions
TRML Stock Forecast
Tourmaline Bio stock forecast is as follows: an average price target of $50.00 (represents a 142.13% upside from TRML’s last price of $20.65) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
TRML Price Target
The average price target for Tourmaline Bio (TRML) is $50.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $50.00. This represents a potential 142.13% upside from TRML's last price of $20.65.
TRML Analyst Ratings
According to 4 Wall Street analysts, Tourmaline Bio's rating consensus is 'Buy'. The analyst rating breakdown for TRML stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tourmaline Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 05, 2024 | Etzer Darout | BMO Capital | $50.00 | $24.03 | 108.07% | 142.13% |
| Mar 21, 2024 | Yatin Suneja | Guggenheim | $50.00 | $28.61 | 74.76% | 142.13% |
| Mar 20, 2024 | Robyn Karnauskas | Truist Financial | $74.00 | $44.67 | 65.66% | 258.35% |
| Mar 20, 2024 | Roger Song | Jefferies | $72.00 | $44.67 | 61.18% | 248.67% |
The latest Tourmaline Bio stock forecast, released on Dec 05, 2024 by Etzer Darout from BMO Capital, set a price target of $50.00, which represents a 108.07% increase from the stock price at the time of the forecast ($24.03), and a 142.13% increase from TRML last price ($20.65).
Tourmaline Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 4 |
| Avg Price Target | $50.00 | $50.00 | $61.50 |
| Last Closing Price | $20.65 | $20.65 | $20.65 |
| Upside/Downside | 142.13% | 142.13% | 197.82% |
In the current month, the average price target of Tourmaline Bio stock is $50.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 142.13% increase as opposed to Tourmaline Bio's last price of $20.65. This month's average price target is down 0.00% compared to last quarter, and down -18.70% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 05, 2024 | BMO Capital | Outperform | Initialise | |
| Nov 04, 2024 | Guggenheim | Buy | Buy | Hold |
| Oct 15, 2024 | Cantor Fitzgerald | Overweight | Initialise | |
| Sep 04, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Tourmaline Bio's last stock rating was published by BMO Capital on Dec 05, 2024. The company Initialise its TRML rating from "null" to "Outperform".
Tourmaline Bio Financial Forecast
Tourmaline Bio Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
Tourmaline Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TRML's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Tourmaline Bio EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict TRML's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Tourmaline Bio's previous annual EBITDA (undefined) of $NaN.
Tourmaline Bio Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Tourmaline Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TRML's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Tourmaline Bio SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Tourmaline Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TRML last annual SG&A of $NaN (undefined).
Tourmaline Bio EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, Tourmaline Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TRML previous annual EPS of $NaN (undefined).